ES2086029T3 - Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada. - Google Patents

Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada.

Info

Publication number
ES2086029T3
ES2086029T3 ES92113187T ES92113187T ES2086029T3 ES 2086029 T3 ES2086029 T3 ES 2086029T3 ES 92113187 T ES92113187 T ES 92113187T ES 92113187 T ES92113187 T ES 92113187T ES 2086029 T3 ES2086029 T3 ES 2086029T3
Authority
ES
Spain
Prior art keywords
permanence
oral administration
pharmaceutical compositions
solid pharmaceutical
long gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92113187T
Other languages
English (en)
Inventor
Pierandrea Esposito
Fabio Carli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectorpharma International SpA
Original Assignee
Vectorpharma International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectorpharma International SpA filed Critical Vectorpharma International SpA
Application granted granted Critical
Publication of ES2086029T3 publication Critical patent/ES2086029T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS SOLIDAS DE ADMINISTRACION ORAL, CON UNA PERMANENCIA EN EL ESTOMAGO PROLONGADA, QUE CONSISTEN EN UNA O MAS SUSTANCIAS INORGANICAS DE GRAN DENSIDAD, UNA O MAS SUSTANCIAS BIOADHESIVAS, UN INGREDIENTE ACTIVO, BIEN POR SI SOLO O MEZCLADO EN UN SISTEMA PORTADOR, ASI COMO EXCIPIENTES, LUBRICANTES Y OTROS MATERIALES NORMALMENTE UTILIZADOS EN LAS FORMULACIONES FARMACEUTICAS.
ES92113187T 1991-08-06 1992-08-03 Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada. Expired - Lifetime ES2086029T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI912212A IT1251153B (it) 1991-08-06 1991-08-06 Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica

Publications (1)

Publication Number Publication Date
ES2086029T3 true ES2086029T3 (es) 1996-06-16

Family

ID=11360543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92113187T Expired - Lifetime ES2086029T3 (es) 1991-08-06 1992-08-03 Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada.

Country Status (5)

Country Link
EP (1) EP0526862B1 (es)
AT (1) ATE134134T1 (es)
DE (1) DE69208299T2 (es)
ES (1) ES2086029T3 (es)
IT (1) IT1251153B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3332426B2 (ja) * 1992-10-02 2002-10-07 太田製薬株式会社 大腸および小腸の検査用ｘ線造影剤
WO1994020074A1 (en) * 1993-03-12 1994-09-15 The Procter & Gamble Company Adsorbate compositions
FR2703250A1 (fr) * 1993-03-30 1994-10-07 Chicouri Marcel Nouvelles compositions pharmaceutiques à base de bismuth et leur procédé de préparation.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
DE4404011A1 (de) * 1994-02-09 1995-08-10 Jenapharm Gmbh Neue, adhäsiv wirkende Zubereitungen für mit Flüssigkeit benetzte Oberflächen, Verfahren und Vorrichtung zur Erfassung der Adhäsionszeit diesbezüglicher Zubereitungen
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CH687810A5 (de) * 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
WO1996039126A2 (en) * 1995-06-06 1996-12-12 Warner-Lambert Company Ranitidine salts on magnesium trisilicate as an adsorbate
ES2112765B1 (es) * 1995-08-02 1999-03-01 Cantabria Ind Farmaceutica Sa Procedimiento para la obtencion de formulaciones de constraste radiologico, para exploraciones gastrointestinales de uso extemporaneo y directo.
DE19533162A1 (de) * 1995-09-08 1997-03-13 Bayer Ag Pharmazeutisches Kombinationspräparat mit Ketoprofen
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
WO1997047323A2 (en) * 1996-06-11 1997-12-18 Zonagen, Inc. Chitosan drug delivery system
JP2001509791A (ja) * 1996-11-27 2001-07-24 ザ、プロクター、エンド、ギャンブル、カンパニー 胃腸障害の治療用組成物及び方法
GB2329334A (en) * 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
ATE321538T1 (de) * 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
JP2002531491A (ja) * 1998-12-11 2002-09-24 ノストラム・ファーマスーティカルズ・インコーポレイテッド ヒドロコロイドおよびセルロースエーテルを含む持続放出性錠剤
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
AU1169601A (en) * 1999-11-16 2001-05-30 Ranbaxy Laboratories Limited Taste masked oral compositions
DE60123384T2 (de) * 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US7527807B2 (en) 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
PL218223B1 (pl) * 2000-06-21 2014-10-31 Cubist Pharmaceuticals Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
GB2373438A (en) * 2001-02-10 2002-09-25 Reckitt & Colmann Prod Ltd Cholesterol lowering compositions
AP1748A (en) * 2001-03-13 2007-06-11 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
MXPA06003101A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US8389008B2 (en) 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
EP2974718A1 (en) 2005-04-29 2016-01-20 Cubist Pharmaceuticals, Inc. Therapeutic compositions
AU2013202344B2 (en) * 2006-08-30 2014-07-17 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
CN101516353B (zh) * 2006-08-30 2013-10-16 雅戈泰克股份公司 包含核心和一个或多个阻挡层的控释口服制剂
CA2662123C (en) 2006-08-30 2015-12-01 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
DE3775880D1 (es) * 1986-09-18 1992-02-20 London School Of Pharmacy Innovations Ltd., London, Gb

Also Published As

Publication number Publication date
ATE134134T1 (de) 1996-02-15
IT1251153B (it) 1995-05-04
DE69208299D1 (de) 1996-03-28
DE69208299T2 (de) 1996-07-18
EP0526862B1 (en) 1996-02-14
ITMI912212A1 (it) 1993-02-07
ITMI912212A0 (it) 1991-08-06
EP0526862A1 (en) 1993-02-10

Similar Documents

Publication Publication Date Title
ES2086029T3 (es) Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada.
DE69532415D1 (de) Schmelzextrudierte oral verabreichbare opioidformulierungen
DE69233130D1 (de) Kaubare zusammensetzung zur arzneimittelfreisetzung
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
DE69520882D1 (de) Arzneizubereitung enthaltend amoxycillin und kaliumclavunalat
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
PT841903E (pt) Composicao farmaceutica oral contendo agentes activos antimicrobianos e pantoprazole com libertacao diferida
DE69425932D1 (de) Schnellauflösliche pharmazeutische Dosierungsformen und Verfahren zu ihrer Herstellung
CR6326A (es) Formulaciones farmaceuticas de liberacion controlada
PT770384E (pt) Composicoes farmaceuticas solidas anidras para utilizacao vaginal
ES2188582T3 (es) El uso de ranitidina-citrato de bismuto en combinacion con claritromicina o claritromicina y tetraciclina en la fabricacion de un medicamento para tratar trastornos gastrointestinales.
ES2187489T3 (es) Composiciones farmaceuticas a base de diclofenac.
DE3783923D1 (de) Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel.
ATE238775T1 (de) Entzündungshemmende pharmazeutische formulierungen
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos
DE69416034D1 (de) Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen
CO4180553A1 (es) Composiciones para el tratamiento de la peridontitis adulta

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526862

Country of ref document: ES